search
Back to results

NAC Effect on Iron Overload and Blood Transfusion in β-thalassemia Major

Primary Purpose

Thalassemia Major

Status
Not yet recruiting
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
n-acetylcystine
Sponsored by
Assiut University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Thalassemia Major focused on measuring N_acetylcystein antioxidant effect

Eligibility Criteria

3 Years - 16 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria: thalassemia major children . On oral iron chelation . Exclusion Criteria: change in the dose of iron chelation within 3 months before enrollement or during study period . Liver impairment Renal impairment patients not adeherent to therapy

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    N_acetylcystein as antioxidant on iron and frequency of blood transfusion in thalassemia major

    Arm Description

    N_acetylcystein administration on single oral dose 10mg /kg for 6 months and it's effect on iron and frequency of blood transfusion before and after its use.

    Outcomes

    Primary Outcome Measures

    Serum ferritin level
    Measuring serum ferritin level (mg/dl) before and after 6 months of acetylcystein administration.

    Secondary Outcome Measures

    Full Information

    First Posted
    January 7, 2023
    Last Updated
    August 22, 2023
    Sponsor
    Assiut University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05777733
    Brief Title
    NAC Effect on Iron Overload and Blood Transfusion in β-thalassemia Major
    Official Title
    The Effect of N_acetylcystein as an Antioxidant on Iron Overload and Frequency of Blood Transfusion in β-thalassemia Major Patients at Assiut Childern Hospital University
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    March 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    March 23, 2024 (Anticipated)
    Primary Completion Date
    April 30, 2024 (Anticipated)
    Study Completion Date
    April 30, 2024 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Assiut University

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The effect of N_acetylcystein as an antioxidant on iron overload and frequency of blood transfusion in β-thalassemia major patients at Assiut Childern Hospital University And its cosubmitted for partial fulfillment of master degree in Pediatrics
    Detailed Description
    Beta thalassemia major it menifests after 6 months of life by severe anemia requiring life-long blood transfusion,which is the the gold standard therapy causing many complications including iron overload which associated to a certain extent with the generation of labile iron in the pathological red blood cell (RBC). The appearance of such forms of iron at the inner and outer cell surfaces exposes the cell to formation of reactive oxygen species (ROS),particularly the hydroxyl radical (·OH) serving as a Fenton reagent, Hydroxyl radical facilitated by membraneassociated iron might be particularly harmful because radical generation would be relatively sequestered from the cell antioxidant capacity and occur directly adjacent to lipid and protein membrane components exceeding cellular defense capacities causing oxidtive stress with prematre cell damage which is the main pathophysiological process in thalassemia . the fact that iron plays a major role in the generation of ROS implies that iron chelators can also serve as antioxidants. Obviously, chelation of iron is one of the major therapeutic goals in thalassemia. Consequently, the orally administered iron chelator deferiprone was able to remove free iron from β- thalassemic red cell membranes in a dose-related fashion, Deferiprone alleviated membrane damage possibly mediated by catalytic iron, such as In a few patients with Hb E/β thalassemia in Thailand, following administration of deferiprone alone for an average of 50 weeks, Hb levels increased concomitant with a decrease in transfusion requirement One possible explanation for this finding is that deferiprone acted like an antioxidant by removing excess free iron from the cells and, as a result, ROS generation was decreased. However, the antioxidant effect of this iron chelator by itself was not sufficient to neutralize the damage induced by ROS Moreover, oral administration of other antioxidant such as vitamin E, which is a lipid antioxidant, exhibited improvement in oxidant-antioxidant balance in the plasma . Another antioxidant that acts primarily on proteins is n_acetylcysteine, which improved certain parameters resulting from oxidative damage to sickle RBCs. here we will give the N_acetylcysteine orally in dose 10mg\kg\day to the thalassemic patients for 6 months and observing its effect as antioxidant on iron overload and the frequency in blood transfusion The ultimate purpose of all these observations is to try to design a combination of antioxidants consisting of an iron chelator, such as deferiprone, vitamin E as antioxidant for the lipids, and N-acetylcysteine as antioxidant for the proteins to decrease the deleterious effect of ORS.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Thalassemia Major
    Keywords
    N_acetylcystein antioxidant effect

    7. Study Design

    Primary Purpose
    Supportive Care
    Study Phase
    Phase 1
    Interventional Study Model
    Single Group Assignment
    Model Description
    N-acetylcystein in dose 10mg /kg single oral dose will be given for 6 months
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    100 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    N_acetylcystein as antioxidant on iron and frequency of blood transfusion in thalassemia major
    Arm Type
    Experimental
    Arm Description
    N_acetylcystein administration on single oral dose 10mg /kg for 6 months and it's effect on iron and frequency of blood transfusion before and after its use.
    Intervention Type
    Drug
    Intervention Name(s)
    n-acetylcystine
    Other Intervention Name(s)
    acetylcystein
    Intervention Description
    Single daily oral administration of N_acetylcystein on dose 10mg /kg/day
    Primary Outcome Measure Information:
    Title
    Serum ferritin level
    Description
    Measuring serum ferritin level (mg/dl) before and after 6 months of acetylcystein administration.
    Time Frame
    6 months from the baseline

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    3 Years
    Maximum Age & Unit of Time
    16 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: thalassemia major children . On oral iron chelation . Exclusion Criteria: change in the dose of iron chelation within 3 months before enrollement or during study period . Liver impairment Renal impairment patients not adeherent to therapy

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    33147909
    Citation
    Mohamed YA, Meabed MH, Ashraf A, Morgan DS, Abdul Latif MG, Abd-Elkareem RM, Ahmed HM. WITHDRAWN:Randomized controlled trial of effect of N-acetylcysteine as an antioxidant on iron overload in children with thalassemia major. Clin Exp Pediatr. 2020 Nov 3. doi: 10.3345/cep.2020.00227. Online ahead of print.
    Results Reference
    background

    Learn more about this trial

    NAC Effect on Iron Overload and Blood Transfusion in β-thalassemia Major

    We'll reach out to this number within 24 hrs